ABBV
XNYSABBVIE INC.
Basic Materials · Pharmaceutical Preparations
$206.26
-0.34 (-0.16%)
15-min delayed
Drag to pan · Scroll to zoom · Hover for OHLC
Snapshot
Loading metrics…
About ABBVIE INC.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
Employees
57,000
Country
US
IPO Date
2012-12-10
Recent News
10 Years, Zero Regrets: The Dividend Stocks I Keep Buying
Yahoo · 1h ago
Datadog And Two Other Stocks That Could Be Trading Below Fair Value Estimates
Yahoo · 2h ago
SKYRIZI® (risankizumab) Secures Listing on Ontario and Alberta Formularies in Ulcerative Colitis
Yahoo · 3h ago
AbbVie Inc. Just Missed Earnings - But Analysts Have Updated Their Models
Yahoo · 2d ago
10 Health Care Stocks With Whale Alerts In Today's Session
Benzinga · 3d ago
Guggenheim Reiterates Buy on AbbVie, Maintains $249 Price Target
Benzinga · 3d ago
Discover 3 Stocks That Might Be Trading Below Estimated Value
Yahoo · 3d ago
Is AbbVie Inc. (ABBV) One of the Best Drug Stocks to Buy According to Analysts?
Yahoo · 3d ago
Analyst Ratings
Loading…
Financials
Loading SEC filings…
Insider Activity
Loading filings…
Related Stocks
Loading peers…
Data is 15-minute delayed, for informational purposes only. Not investment advice. Prices via Massive.com consolidated feed. Fundamentals via FinancialModelingPrep. News via Finnhub.